Spiden, a Pfäffikon, Switzerland-based company which specializes in non-invasive biomarker monitoring technology, raised $15M in additional funding.
The round saw participation from undisclosed existing investors and Board members, as well as new investors.
The company intends to use the funds to finalize its initial, now 6-year long phase of R&D, aimed at cracking complete calibration-free monitoring, as well as securing a pathway to miniaturization of its portable product to a wearable format.
Led by Leo Grünstein, Founder and CEO, Spiden is a tech startup that works the field of personalized health monitoring. Its approach combines spectroscopy techniques and machine learning to achieve real-time, non-invasive monitoring of various biomarkers. Spiden’s mission is to use its wrist-worn wearable, becomes the norm, facilitating prevention and early detection, by empowering users with personalized control over their health and longevity. It employs a team of >70 staff, including >50 PhDs and university professors, operating out of its lab facilities Switzerland.
Commenting on the news, Leo Grünstein said “We aim to help customers around the world take control of their health through non-invasive access to real-time biomarker data and actionable, evidence-based insights to improve their well-being and longevity.”
FinSMEs
31/01/2024